NASDAQ NMS - GLOBAL MARKET · COAG
+9.77% · +$3.31 · Vol 313.4K
Market closed · last close 4:00 PM ET · price as of 16:00:31 ET
Hemab Therapeutics Holdings Inc

Hemab Therapeutics Holdings Inc

Biotechnology
$37.20
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is COAG moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for COAG are being assembled.
About Hemab Therapeutics Holdings Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2026
Country
US

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$34.00
Day high
$38.45
Day low
$33.57
Previous close
$33.89
52W high
$38.45
-3.25% from high
52W low
$24.99
91% of range
Market cap
$1.6B
EPS
$-1.4462
Shares out
46.7M
Volume
313.4K
VWAP
$36.81
Price history computed in-house
1W
+18.93%
1M
+38.03%
SMA 50 $30.41 · above
SMA 200 $30.41 · above
52W position 91%
Veridion warehouse edge

Warehouse intelligence for COAG.

Veridion Score
55
0: Not reported1: 522: 563: Not reported4: 825: Not reported
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

COAG insider activity

Hemab Therapeutics Holdings Inc

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for COAG.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

COAG contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for COAG in this window.
Lobbying spend

COAG lobbying filings, year to date.

Registered lobbying filings matched to Hemab Therapeutics Holdings Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for COAG in this window.
Latest news · COAG
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for COAG.
Options
Sovereign unlock shows live options positioning for COAG.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.